GTF2H2C

Summary

GTF2H2C (GTF2H2 family member C, HGNC:31394) is a protein-coding gene on chromosome 5q13.2, encoding General transcription factor IIH subunit 2-like protein (Q6P1K8). Component of the core-TFIIH basal transcription factor involved in nucleotide excision repair (NER) of DNA and, when complexed to CAK, in RNA transcription by RNA polymerase II.

Enables RNA polymerase II general transcription initiation factor activity. Involved in G protein-coupled receptor internalization and transcription initiation at RNA polymerase II promoter. Located in nuclear speck. Part of core TFIIH complex portion of holo TFIIH complex and transcription factor TFIID complex.

Source: NCBI Gene 728340 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 5 total
• MANE Select transcript: NM_001376000

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31394
Approved symbol	GTF2H2C
Name	GTF2H2 family member C
Location	5q13.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000183474
Ensembl biotype	protein_coding
Entrez	728340

Gene structure

Transcript identifiers

Ensembl transcripts: 32 — 22 protein_coding, 4 nonsense_mediated_decay, 4 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000380729, ENST00000446221, ENST00000502599, ENST00000502619, ENST00000503604, ENST00000505737, ENST00000506129, ENST00000507595, ENST00000508325, ENST00000510979, ENST00000511629, ENST00000512736, ENST00000513959, ENST00000514069, ENST00000514162, ENST00000877333, ENST00000877334, ENST00000877335, ENST00000877336, ENST00000877337, ENST00000877338, ENST00000877339, ENST00000911365, ENST00000911366, ENST00000911367, ENST00000962641, ENST00000962642, ENST00000962643, ENST00000962644, ENST00000962645, ENST00000962646, ENST00000962647

RefSeq mRNA: 9 — MANE Select: NM_001376000 NM_001098728, NM_001375998, NM_001375999, NM_001376000, NM_001376001, NM_001376002, NM_001376003, NM_001376005, NM_001376006

CCDS: CCDS43325

Canonical transcript exons

ENST00000380729 — 17 exons

Exon	Start	End
ENSE00001669926	69562673	69562770
ENSE00002020622	69592079	69595221
ENSE00003459876	69566967	69567053
ENSE00003461104	69586254	69586356
ENSE00003500955	69572445	69572550
ENSE00003502052	69579021	69579108
ENSE00003521738	69566589	69566625
ENSE00003548190	69566131	69566208
ENSE00003559216	69567727	69567777
ENSE00003571433	69568153	69568207
ENSE00003632837	69585594	69585697
ENSE00003644836	69590328	69590367
ENSE00003655954	69565100	69565188
ENSE00003668680	69582366	69582429
ENSE00003671763	69579757	69579864
ENSE00003686073	69578712	69578802
ENSE00003905674	69560191	69560403

Expression profiles

Bgee: expression breadth ubiquitous, 261 present calls, max score 95.13.

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	95.13	gold quality
postcentral gyrus	UBERON:0002581	90.96	gold quality
ventricular zone	UBERON:0003053	89.50	gold quality
monocyte	CL:0000576	89.38	gold quality
mononuclear cell	CL:0000842	89.02	gold quality
stromal cell of endometrium	CL:0002255	88.97	gold quality
adrenal tissue	UBERON:0018303	88.85	gold quality
parietal lobe	UBERON:0001872	88.82	gold quality
leukocyte	CL:0000738	88.62	gold quality
corpus callosum	UBERON:0002336	88.07	gold quality
islet of Langerhans	UBERON:0000006	87.88	gold quality
metanephros cortex	UBERON:0010533	87.31	gold quality
ganglionic eminence	UBERON:0004023	87.16	gold quality
colonic epithelium	UBERON:0000397	86.70	gold quality
right lobe of thyroid gland	UBERON:0001119	86.44	gold quality
right ovary	UBERON:0002118	86.38	gold quality
endocervix	UBERON:0000458	86.04	gold quality
body of pancreas	UBERON:0001150	86.00	gold quality
left lobe of thyroid gland	UBERON:0001120	85.67	gold quality
pancreas	UBERON:0001264	85.62	gold quality
cortical plate	UBERON:0005343	85.57	gold quality
left uterine tube	UBERON:0001303	85.13	gold quality
thyroid gland	UBERON:0002046	85.00	gold quality
body of uterus	UBERON:0009853	84.96	gold quality
left ovary	UBERON:0002119	84.81	gold quality
blood	UBERON:0000178	84.80	gold quality
ectocervix	UBERON:0012249	84.78	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.72	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.68	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	84.53	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.34
E-MTAB-7303	no	14.28

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

29 targeting GTF2H2C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4719	99.73	72.10	3329
HSA-MIR-217-5P	99.49	69.93	1419
HSA-MIR-4735-5P	99.43	68.49	1780
HSA-MIR-183-3P	99.41	69.41	1598
HSA-MIR-888-5P	99.30	70.15	1855
HSA-MIR-6807-3P	99.15	69.23	1275
HSA-MIR-4504	99.10	69.14	1328
HSA-MIR-501-5P	98.77	68.88	1328
HSA-MIR-4680-3P	98.64	68.60	2093
HSA-MIR-5089-5P	98.45	66.06	1388
HSA-MIR-4684-3P	98.24	69.91	1075
HSA-MIR-550B-3P	95.43	67.73	599

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	gtf2h2	ENSDARG00000016514
mus_musculus	Gtf2h2	ENSMUSG00000021639
rattus_norvegicus	Gtf2h2	ENSRNOG00000018230
drosophila_melanogaster	Ssl1	FBGN0037202
caenorhabditis_elegans		WBGENE00011814

Paralogs (1): GTF2H2 (ENSG00000145736)

Protein

Protein identifiers

General transcription factor IIH subunit 2-like protein — Q6P1K8 (reviewed: Q6P1K8)

Alternative names: General transcription factor IIH polypeptide 2-like protein

All UniProt accessions (6): D6RAW1, D6RGC9, D6RID8, D6RIT7, D6RJD3, Q6P1K8

UniProt curated annotations — full annotation on UniProt →

Function. Component of the core-TFIIH basal transcription factor involved in nucleotide excision repair (NER) of DNA and, when complexed to CAK, in RNA transcription by RNA polymerase II.

Subcellular location. Nucleus.

Similarity. Belongs to the GTF2H2 family.

RefSeq proteins (9): NP_001092198, NP_001362927, NP_001362928, NP_001362929, NP_001362930, NP_001362931, NP_001362932, NP_001362934, NP_001362935 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002035	VWF_A	Domain
IPR004595	TFIIH_C1-like_dom	Domain
IPR007198	Ssl1-like	Domain
IPR012170	TFIIH_SSL1/p44	Family
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR013087	Znf_C2H2_type	Domain
IPR036465	vWFA_dom_sf	Homologous_superfamily
IPR046349	C1-like_sf	Homologous_superfamily

Pfam: PF04056, PF07975

UniProt features (5 total): chain 1, domain 1, zinc finger region 1, modified residue 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6P1K8-F1	84.05	0.49

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 95

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 51 (showing top): GOBP_NUCLEOTIDE_EXCISION_REPAIR, SMID_BREAST_CANCER_LUMINAL_B_UP, GOBP_DNA_DAMAGE_RESPONSE, KIM_GERMINAL_CENTER_T_HELPER_UP, GOCC_RNA_POLYMERASE_COMPLEX, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, GOCC_TRANSFERASE_COMPLEX_TRANSFERRING_PHOSPHORUS_CONTAINING_GROUPS, GOCC_RNA_POLYMERASE_II_TRANSCRIPTION_REGULATOR_COMPLEX, GOCC_NUCLEAR_SPECK, GOCC_NUCLEAR_CYCLIN_DEPENDENT_PROTEIN_KINASE_HOLOENZYME_COMPLEX, GOCC_TRANSFERASE_COMPLEX, GOCC_NUCLEAR_BODY, GOCC_PROTEIN_KINASE_COMPLEX, CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP, GOCC_TRANSCRIPTION_REGULATOR_COMPLEX

GO Biological Process (5): nucleotide-excision repair (GO:0006289), DNA-templated transcription (GO:0006351), regulation of transcription by RNA polymerase II (GO:0006357), DNA repair (GO:0006281), DNA damage response (GO:0006974)

GO Molecular Function (3): zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (4): transcription factor TFIIH core complex (GO:0000439), transcription factor TFIIH holo complex (GO:0005675), nuclear speck (GO:0016607), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulator complex	2
DNA repair	1
gene expression	1
RNA biosynthetic process	1
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
DNA metabolic process	1
DNA damage response	1
cellular response to stress	1
transition metal ion binding	1
binding	1
cation binding	1
transcription factor TFIIH core complex	1
RNA polymerase II, holoenzyme	1
nuclear cyclin-dependent protein kinase holoenzyme complex	1
carboxy-terminal domain protein kinase complex	1
nuclear ribonucleoprotein granule	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

862 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GTF2H2C	GTF2H3	Q13889	797
GTF2H2C	GTF2H1	P32780	770
GTF2H2C	ERCC3	P19447	754
GTF2H2C	GTF2H4	Q92759	738
GTF2H2C	ERCC8	Q13216	684
GTF2H2C	ERCC1	P07992	671
GTF2H2C	SERF1A	O75920	583
GTF2H2C	ERCC2	P18074	572
GTF2H2C	MNAT1	P51948	542
GTF2H2C	CDK7	P50613	530
GTF2H2C	NAIP	Q13075	506
GTF2H2C	FAM72B	Q86X60	474
GTF2H2C	SMN1	Q16637	474
GTF2H2C	DHRS4L2	Q6PKH6	473
GTF2H2C	TCAF1	Q9Y4C2	461

IntAct

41 interactions, top by confidence:

A	B	Type	Score
GTF2H1	CDK7	psi-mi:“MI:0915”(physical association)	0.820
GTF2H3	GTF2H2C	psi-mi:“MI:0915”(physical association)	0.800
GTF2H2C	GTF2H3	psi-mi:“MI:0915”(physical association)	0.800
GTF2H3	ERCC3	psi-mi:“MI:0914”(association)	0.640
ERCC2	GTF2H2C	psi-mi:“MI:0915”(physical association)	0.560
DZIP3	GTF2H2C	psi-mi:“MI:0915”(physical association)	0.560
GTF2H2C	ERCC2	psi-mi:“MI:0915”(physical association)	0.560
GTF2H2C	DZIP3	psi-mi:“MI:0915”(physical association)	0.560
GTF2H2C	FAM43A	psi-mi:“MI:0915”(physical association)	0.560
NR5A2	GTF2H2C	psi-mi:“MI:0915”(physical association)	0.560
GTF2H2C	NTAQ1	psi-mi:“MI:0915”(physical association)	0.560
GTF2H2C	ERCC3	psi-mi:“MI:0914”(association)	0.530
DYNLRB2	PAFAH1B1	psi-mi:“MI:0914”(association)	0.510
SUV39H1	GTF2H2C	psi-mi:“MI:0915”(physical association)	0.370
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
CCDC40	VAPB	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
GTF2H2C	GTF2H2C	psi-mi:“MI:0914”(association)	0.350
PRDM11	ERCC3	psi-mi:“MI:0914”(association)	0.350
CDK7	ACACB	psi-mi:“MI:0914”(association)	0.350
CDC7	ERCC1	psi-mi:“MI:0914”(association)	0.350
CDK7	ERCC1	psi-mi:“MI:0914”(association)	0.350
GTF2H4	TUSC2	psi-mi:“MI:0914”(association)	0.350
GTF2H4	HSPA8	psi-mi:“MI:0914”(association)	0.350
EAF1	C1orf226	psi-mi:“MI:0914”(association)	0.350
HIRIP3	GPX1	psi-mi:“MI:0914”(association)	0.350

BioGRID (92): GTF2H2C_2 (Two-hybrid), GTF2H2C_2 (Two-hybrid), GTF2H2C_2 (Two-hybrid), GTF2H2C (Affinity Capture-MS), GTF2H1 (Affinity Capture-MS), GTF2H3 (Affinity Capture-MS), GTF2H4 (Affinity Capture-MS), ERCC3 (Affinity Capture-MS), PTS (Affinity Capture-MS), GALC (Affinity Capture-MS), GTF2H2C (Co-fractionation), GTF2H2C (Co-fractionation), GTF2H2C (Co-fractionation), GTF2H2C_2 (Co-fractionation), GTF2H2C_2 (Co-fractionation)

ESM2 similar proteins: A0A1L8F5J9, A0JN27, F1LTR1, F1NBL0, O15294, P35438, P35439, P56558, P61201, P61202, P61203, P61599, P61600, P63138, P79101, P81436, Q03555, Q05586, Q13888, Q15303, Q27HV0, Q2PFM2, Q2TBV5, Q4L208, Q58ED9, Q5R1P0, Q5SP67, Q5ZJ75, Q61527, Q62956, Q6IQT4, Q6IR75, Q6P1K8, Q6P632, Q7ZXR3, Q8BUV3, Q8C6G8, Q8CGY8, Q8R4D1, Q91854

Diamond homologs: A0JN27, O74995, P34567, Q04673, Q13888, Q2TBV5, Q6P1K8, Q86KZ2, Q9JIB4, Q9ZVN9

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
GTF2H2C	“form complex”	TFIIH	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 33 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection	7	114.2×	9e-12
RNA Pol II CTD phosphorylation and interaction with CE	7	114.2×	9e-12
mRNA Capping	7	106.6×	1e-11
Formation of the Early Elongation Complex	7	94.0×	1e-11
Formation of the HIV-1 Early Elongation Complex	7	94.0×	1e-11
RNA Polymerase I Transcription Termination	7	91.4×	2e-11
Global Genome Nucleotide Excision Repair (GG-NER)	5	91.4×	1e-08
Formation of Incision Complex in GG-NER	8	81.2×	7e-12

GO biological processes:

GO term	Partners	Fold	FDR
nucleotide-excision repair	7	89.4×	4e-10
transcription initiation at RNA polymerase II promoter	5	62.4×	2e-06
DNA repair	7	14.9×	3e-05
transcription by RNA polymerase II	6	14.1×	3e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

5 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	2
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2096 predictions. Top by Δscore:

Variant	Effect	Δscore
5:69565095:TACA:T	acceptor_loss	1.0000
5:69565098:A:AG	acceptor_gain	1.0000
5:69565099:G:GG	acceptor_gain	1.0000
5:69565099:GA:G	acceptor_gain	1.0000
5:69565099:GAT:G	acceptor_gain	1.0000
5:69565099:GATT:G	acceptor_gain	1.0000
5:69565099:GATTA:G	acceptor_gain	1.0000
5:69565184:ACATG:A	donor_gain	1.0000
5:69565186:ATGG:A	donor_loss	1.0000
5:69565187:TGG:T	donor_loss	1.0000
5:69565188:GGTAA:G	donor_loss	1.0000
5:69565189:G:GA	donor_loss	1.0000
5:69565189:G:GG	donor_gain	1.0000
5:69565190:T:A	donor_loss	1.0000
5:69566129:AG:A	acceptor_gain	1.0000
5:69566130:GG:G	acceptor_gain	1.0000
5:69566130:GGGA:G	acceptor_gain	1.0000
5:69566965:A:AG	acceptor_gain	1.0000
5:69566966:G:GG	acceptor_gain	1.0000
5:69566966:GAT:G	acceptor_gain	1.0000
5:69566966:GATGC:G	acceptor_gain	1.0000
5:69567049:TAAAG:T	donor_loss	1.0000
5:69567050:AAAGG:A	donor_loss	1.0000
5:69567051:AAGG:A	donor_loss	1.0000
5:69567052:AGG:A	donor_loss	1.0000
5:69567054:G:GA	donor_loss	1.0000
5:69567055:T:G	donor_loss	1.0000
5:69567061:T:G	donor_gain	1.0000
5:69567725:A:AG	acceptor_gain	1.0000
5:69567726:G:GG	acceptor_gain	1.0000

AlphaMissense

2593 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:69582368:T:C	F254L	1.000
5:69582370:T:A	F254L	1.000
5:69582370:T:G	F254L	1.000
5:69585685:T:C	C305R	1.000
5:69586281:T:C	L318S	1.000
5:69565165:G:C	W11C	0.999
5:69565165:G:T	W11C	0.999
5:69566131:G:C	W19C	0.999
5:69566131:G:T	W19C	0.999
5:69566624:T:C	M57T	0.999
5:69566970:C:A	R59S	0.999
5:69567765:T:A	N99K	0.999
5:69567765:T:G	N99K	0.999
5:69567772:A:C	S102R	0.999
5:69567774:T:A	S102R	0.999
5:69567774:T:G	S102R	0.999
5:69578755:A:C	S172R	0.999
5:69578757:C:A	S172R	0.999
5:69578757:C:G	S172R	0.999
5:69582369:T:C	F254S	0.999
5:69582369:T:G	F254C	0.999
5:69585643:T:C	C291R	0.999
5:69585645:C:G	C291W	0.999
5:69585652:T:C	C294R	0.999
5:69585687:T:G	C305W	0.999
5:69585694:T:C	C308R	0.999
5:69585695:G:A	C308Y	0.999
5:69585696:T:G	C308W	0.999
5:69586257:T:C	L310P	0.999
5:69586281:T:G	L318W	0.999

dbSNP variants (sampled 300 via entrez): RS1000064786 (5:69568163 T>C), RS1001071174 (5:69564610 C>G), RS1001081306 (5:69564108 C>T), RS1001372131 (5:69559032 C>G), RS1002312144 (5:69565234 T>A), RS1002586365 (5:69574263 C>T), RS1002986590 (5:69577638 T>A), RS1003042827 (5:69560771 T>G), RS1003578495 (5:69569425 A>G), RS1003874984 (5:69561256 A>G), RS1003884855 (5:69560871 C>T), RS1003986003 (5:69581290 GA>G), RS1004881791 (5:69559796 C>T), RS1004891664 (5:69559239 A>G), RS1005080672 (5:69572163 A>C)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST007637_45	Diffusing capacity of carbon monoxide	6.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009369	diffusing capacity of the lung for carbon monoxide

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

10 total (human), top 10 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression	1
sodium arsenite	decreases expression	1
pyrrolidine dithiocarbamic acid	affects cotreatment, increases expression	1
bathocuproine sulfonate	affects cotreatment, increases expression	1
Glyphosate	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	affects methylation	1
Doxorubicin	decreases expression	1
Aflatoxin B1	decreases methylation	1
Particulate Matter	increases abundance, increases expression	1

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists